Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lapatinib plus vinorelbine in ErbB2-positive metastatic breast cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Navelbine (vinorelbine)
• Tykerb (lapatinib)

Snippet

Sponsor: Central European Cooperative Oncology Group | Conditions: Metastatic Breast Cancer | Phase 2 | Status: TERMINATED